BlackRock led a $100m Series C round in Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence to design new drugs, with participation from Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital. This new capital will be used to support Exscientia’s platform development towards autonomous drug design. In addition, the company will extend its proprietary pipeline into clinical trials and expand existing capabilities in biological analytics that support target selection and portfolio development.